Key result
In vitro 3D model bench testing altered the treatment strategy in all 15 patients and led to the selection of smaller Venus P-valves compared to conventional balloon sizing.
Why the study?
Due to wide variations in morphology, size, and dynamics, selecting optimal valve size and location poses great difficulty in percutaneous pulmonary valve implantation.
Does in vitro bench testing using patient-specific 3D models improve valve size selection and procedural planning in patients undergoing percutaneous pulmonary valve implantation?
Observational (n=15)
No
Does in vitro bench testing using patient-specific 3D models improve valve size selection and procedural planning in patients undergoing percutaneous pulmonary valve implantation?
Patient-specific 3D-printed models for PPVI planning safely reduced the need for significant valve oversizing compared to conventional balloon-sizing techniques, optimizing procedural success.
Answers are grounded in this paper and cite their sources.
May support 3D modeling over balloon sizing for P-valve selection; leaves open whether smaller valves improve clinical outcomes.
BACKGROUND: Due to the wide variety of morphology, size, and dynamics, selecting an optimal valve size and location poses great difficulty in percutaneous pulmonary valve implantation (PPVI). This study aimed to report our experience with in vitro bench testing using patient-specific three-dimensional (3D)-printed models for planning PPVI with the Venus P-valve. METHODS: Patient-specific 3D soft models were generated using PolyJet printing with a compliant synthetic material in 15 patients scheduled to undergo PPVI between July 2018 and July 2020 in Central China Fuwai Hospital of Zhengzhou University. RESULTS: 3D model bench testing altered treatment strategy in all patients (100%). One patient was referred for surgery because testing revealed that even the largest Venus P-valve would not anchor properly. In the remaining 14 patients, valve size and/or implantation location was altered to avoid valve migration and/or compression coronary artery. In four patients, it was decided to change the point anchoring because of inverted cone-shaped right ventricular outflow tract (RVOT) ( n = 2) or risk of compression coronary artery ( n = 2). Concerning sizing, we found that an oversize of 2-5 mm suffices. Anchoring of the valve was dictated by the flaring of the in- and outflow portion in the pulmonary artery. PPVI was successful in all 14 patients (absence of valve migration, no coronary compression, and none-to-mild residual pulmonary regurgitation [PR]). The diameter of the Venus P-valve in the 3D simulation group was significantly smaller than that of the conventional planning group (36 [2] vs. 32 [4], Z = -3.77, P <0.001). CONCLUSIONS: In vitro testing indicated no need to oversize the Venus P-valve to the degree recommended by the balloon-sizing technique, as 2-5 mm sufficed.
No takes yet. Share an insight, caveat, or question.
Han et al. (2023) conducted an observational in Dilated right ventricular outflow tract and chronic severe pulmonary regurgitation (n=15). 3D model bench testing for PPVI planning vs. Conventional planning (balloon sizing) was evaluated on Venus P-valve diameter selection (p=<0.001). In vitro 3D model bench testing altered the treatment strategy in all 15 patients and led to the selection of smaller Venus P-valves compared to conventional balloon sizing.
Synapse has enriched 10 related papers. Consider them for comparative context: